The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).
Age 35 to ≤ 80 years.
Lp(a) ≥ 200 nmol/L during screening.
Angiographic evidence of coronary artery disease in at least one major epicardial vessel on screening CCTA.
History of myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or coronary revascularization by percutaneous coronary intervention.
History of coronary artery bypass graft (CABG).
Moderate to severe renal dysfunction.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN), or total bilirubin (TBL) > 2 x ULN during screening.
History of hemorrhagic stroke.